Qilu pharmaceutical "capecitabine tablets" first passed the consistency evaluation

On February 10, Qilu pharmaceutical capecitabine tablets (0.5g, 0.15g) passed the consistency evaluation and became the first in China Capecitabine is an anti-tumor drug, which is suitable for adjuvant chemotherapy of colon cancer It is mainly used in Dukes' C stage, after radical resection of primary tumor, and single drug adjuvant therapy of colon cancer patients who are suitable for fluoropyrimidine alone The drug belongs to 5-fluorouracil precursor drug, which has the advantage of selective targeting, no cytotoxicity, can be aggregated in tumor cells and activated as 5-fluorouracil, so as to minimize the damage of 5-fluorouracil to normal human cells, and convenient for oral administration Up to now, Qilu pharmaceutical has a total of 24 varieties passed the consistency evaluation, and 15 of them are the first in China Among them, there are 22 oral preparations and 2 injections.